K201

K201 is a code name associated with two distinct therapeutic candidates. Most prominently, it refers to **JTV-519**, a 1,4-benzothiazepine derivative originally discovered by Japan Tobacco and later developed by Sequel Pharmaceuticals for cardiovascular indications. JTV-519 acts as a multi-channel blocker (inhibiting sodium, potassium, and L-type calcium channels) and a stabilizer of the **Ryanodine Receptor 2 (RyR2)**. Its primary mechanism involves increasing the binding affinity of calstabin2 (FKBP12.6) to RyR2, which prevents the diastolic calcium leak from the sarcoplasmic reticulum associated with arrhythmias and heart failure. Separately, the name K201 was used by **Moberg Derma** for a topical, steroid-free treatment for mild to moderate **atopic eczema**. This formulation was designed to restore the skin barrier, enhance hydration, and provide antimicrobial effects without inducing resistance. Both versions of K201 reached Phase II clinical development in their respective indications before development progress stalled.

Other names

JTV-519JTV519JTV 519